In preclinical studies, CB-839 induced OXPHOS reduction, suppressed AML cell proliferation, triggered cell death [15, 16, 118], and showed synergy with venetoclax and gilteritinib and induced differentiation in IDH1- and IDH2-mutant AML cells in vitro [16, 17, 118, 120]. The gene discussed is IDH2; the disease is acute myeloid leukemia.